SCHEDULE: Paradigm BioCapital Discloses 5% Stake in Lexeo Therapeutics

Paradigm BioCapital Advisors LP and related entities have reported a 5.0% beneficial ownership stake in Lexeo Therapeutics, Inc. common stock.

Summary

• Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, and Senai Asefaw, M.D. each beneficially own 3,671,999 shares of Lexeo Therapeutics, Inc. common stock.
• This ownership represents 5.0% of the total class of common stock outstanding.
• Paradigm BioCapital International Fund Ltd., a private investment vehicle, beneficially owns 3,244,093 shares, representing 4.4% of the class.
• The shares were acquired for investment purposes and not with the intent to change or influence the control of Lexeo Therapeutics, Inc.
• The beneficial ownership percentages are based on 72,987,327 shares of Common Stock outstanding as of November 3, 2025, as reported by Lexeo Therapeutics, Inc. in its Form 10-Q filed on November 5, 2025.

Sentiment

Score: 6

Explanation: The filing indicates a significant institutional investment, which is generally a positive signal of confidence. However, it is a passive investment and does not provide operational or financial updates, thus limiting the overall sentiment impact.

Positives

• The disclosure of a 5.0% beneficial ownership by Paradigm BioCapital, an institutional investor, signals a vote of confidence in Lexeo Therapeutics, Inc. from a significant market participant.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Lexeo Therapeutics, Inc.'s future performance or operations.

Management Comments

• The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

The entry of a new institutional investor, Paradigm BioCapital, into Lexeo Therapeutics, Inc. with a significant 5% stake, even if passive, can be viewed as a positive indicator of interest in the biopharmaceutical sector and Lexeo's specific pipeline or market position.

Stakeholder Impact

• Shareholders may perceive the institutional investment as a positive signal, potentially increasing investor confidence and market interest in Lexeo Therapeutics, Inc.

Key Dates

Recommendation

The disclosure of a 5% passive stake by an institutional investor like Paradigm BioCapital suggests a vote of confidence in Lexeo Therapeutics, Inc. While this doesn't fundamentally alter the company's operational outlook or financial performance, it introduces a significant institutional holder, which can be a positive market signal. For a seasoned investor, this information alone is not sufficient to warrant a 'buy' or 'sell' recommendation, but it supports maintaining a 'hold' position, acknowledging the increased institutional interest without new fundamental data.

Keywords

Lexeo Therapeutics, Paradigm BioCapital, Schedule 13G, beneficial ownership, common stock, institutional investment, biotechnology